Transcatheter closure of a perimembranous ventricular septal defect with Nit-Occlud Lê VSD Coil: A French multicentre study.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 30 06 2019
revised: 18 11 2019
accepted: 21 11 2019
pubmed: 27 1 2020
medline: 23 6 2020
entrez: 27 1 2020
Statut: ppublish

Résumé

Transcatheter perimembranous ventricular septal defect (pmVSD) closure remains challenging and is seldom used in France given the risk of atrioventricular block (AVB). pmVSD closure with the Nit-Occlud Lê VSD coil was recently introduced in France as an alternative to occluder devices. To study the safety and feasibility of pmVSD closure with the Nit-Occlud Lê VSD coil. All consecutives cases of pmVSD closure with the Nit-Occlud Lê VSD coil in 20 tertiary French centres were included between January 2015 and December 2018. Among 46 procedures in five centres, indications for pmVSD closure were left ventricle overload (76.1%), exertional dyspnoea (17.4%), history of infective endocarditis (4.3%) and mild pulmonary hypertension (2.2%). The median (interquartile [IQR]) age of the patients was 13.9 (5.7-31.8) years. Aneurismal tissue was identified in 91.3% of patients. VSD median (IQR) size was 8 (7-10) mm on the left ventricle side and 5 (4-6) mm on the right ventricle side. Implantation was successful in 40 patients (87.0%; 95% confidence interval [CI] 73.7-95.1%). Severe complications occurred in six patients (13.0%, 95% CI 4.9-26.3%), mainly severe haemolysis (8.7%, 95% CI 2.4-20.8%). One aortic valve lesion required surgical aortic valvuloplasty. Occurrence of severe complications was significantly related to the presence of haemolysis (P=0.001), residual shunt (P=0.007) and multi-exit VSD (P=0.005). Residual shunt was observed in 40% of cases with the implanted device shortly after closure and 15% after a median follow-up of 27 months. No immediate or delayed device embolization or complete AVB was recorded. pmVSD closure with the Nit-Occlud Lê VSD Coil is feasible in older children and adults. However, residual shunting (leading to haemolysis) is a dreaded complication that should not be tolerated. pmVSD closure with the Nit-Occlud Lê VSD as a therapeutic strategy remains controversial and is limited to selected patients.

Sections du résumé

BACKGROUND BACKGROUND
Transcatheter perimembranous ventricular septal defect (pmVSD) closure remains challenging and is seldom used in France given the risk of atrioventricular block (AVB). pmVSD closure with the Nit-Occlud Lê VSD coil was recently introduced in France as an alternative to occluder devices.
AIMS OBJECTIVE
To study the safety and feasibility of pmVSD closure with the Nit-Occlud Lê VSD coil.
METHODS METHODS
All consecutives cases of pmVSD closure with the Nit-Occlud Lê VSD coil in 20 tertiary French centres were included between January 2015 and December 2018.
RESULTS RESULTS
Among 46 procedures in five centres, indications for pmVSD closure were left ventricle overload (76.1%), exertional dyspnoea (17.4%), history of infective endocarditis (4.3%) and mild pulmonary hypertension (2.2%). The median (interquartile [IQR]) age of the patients was 13.9 (5.7-31.8) years. Aneurismal tissue was identified in 91.3% of patients. VSD median (IQR) size was 8 (7-10) mm on the left ventricle side and 5 (4-6) mm on the right ventricle side. Implantation was successful in 40 patients (87.0%; 95% confidence interval [CI] 73.7-95.1%). Severe complications occurred in six patients (13.0%, 95% CI 4.9-26.3%), mainly severe haemolysis (8.7%, 95% CI 2.4-20.8%). One aortic valve lesion required surgical aortic valvuloplasty. Occurrence of severe complications was significantly related to the presence of haemolysis (P=0.001), residual shunt (P=0.007) and multi-exit VSD (P=0.005). Residual shunt was observed in 40% of cases with the implanted device shortly after closure and 15% after a median follow-up of 27 months. No immediate or delayed device embolization or complete AVB was recorded.
CONCLUSION CONCLUSIONS
pmVSD closure with the Nit-Occlud Lê VSD Coil is feasible in older children and adults. However, residual shunting (leading to haemolysis) is a dreaded complication that should not be tolerated. pmVSD closure with the Nit-Occlud Lê VSD as a therapeutic strategy remains controversial and is limited to selected patients.

Identifiants

pubmed: 31982353
pii: S1875-2136(20)30015-2
doi: 10.1016/j.acvd.2019.11.004
pii:
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

104-112

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

Ali Houeijeh (A)

Pediatric Cardiology Department, Lille University Hospital, University Nord de France, 59000 Lille, France; Perinatal Growth and Health, University of Lille, EA4489, 59000 Lille, France; Department of Neonatology, CHU Lille, Jeanne-de-Flandre Hospital, 59000 Lille, France. Electronic address: dalih77@gmail.com.

François Godart (F)

Pediatric Cardiology Department, Lille University Hospital, University Nord de France, 59000 Lille, France; Perinatal Growth and Health, University of Lille, EA4489, 59000 Lille, France.

Zakaria Jalal (Z)

Department of Pediatric and Adult Congenital Cardiology, Bordeaux University Hospital (CHU), 33600 Pessac, France; IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, 33600 Pessac-Bordeaux, France; INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, U1045, 33000 Bordeaux, France.

Caroline Ovaert (C)

Pediatric Cardiology Department, Marseille University Hospital, 13000 Marseille, France.

François Heitz (F)

Pediatric Cardiology Department, Toulouse University Hospital, 31000 Toulouse, France.

Pierre Mauran (P)

Pediatric Cardiology Department, Reims University Hospital, 51100 Reims, France.

Alban-Elouen Baruteau (AE)

Pediatric Cardiology Department, University Hospital of Nantes, 44000 Nantes, France.

Lisa Guirguis (L)

Congenital Heart Diseases Unit, Brompton Royal Hospital, SW3 6NP London, UK.

Khaled Hadeed (K)

Pediatric Cardiology Department, Toulouse University Hospital, 31000 Toulouse, France.

Jean-Benoit Baudelet (JB)

Pediatric Cardiology Department, Lille University Hospital, University Nord de France, 59000 Lille, France; Perinatal Growth and Health, University of Lille, EA4489, 59000 Lille, France; Department of Neonatology, CHU Lille, Jeanne-de-Flandre Hospital, 59000 Lille, France.

Xavier Iriart (X)

Department of Pediatric and Adult Congenital Cardiology, Bordeaux University Hospital (CHU), 33600 Pessac, France; IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, 33600 Pessac-Bordeaux, France; INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, U1045, 33000 Bordeaux, France.

Philippe Aldebert (P)

Pediatric Cardiology Department, Marseille University Hospital, 13000 Marseille, France.

Philippe Acar (P)

Pediatric Cardiology Department, Toulouse University Hospital, 31000 Toulouse, France.

Alain Fraisse (A)

Congenital Heart Diseases Unit, Brompton Royal Hospital, SW3 6NP London, UK.

Ender Odemis (E)

Department of Pediatric Cardiology, Mehmet Akif Ersoy Cardiovascular Research and Training Hospital, Istanbul, Turkey.

Clément Karsenty (C)

Pediatric Cardiology Department, Toulouse University Hospital, 31000 Toulouse, France.

Jean Benoit Thambo (JB)

Department of Pediatric and Adult Congenital Cardiology, Bordeaux University Hospital (CHU), 33600 Pessac, France; IHU Liryc, Electrophysiology and Heart Modeling Institute, Fondation Bordeaux Université, 33600 Pessac-Bordeaux, France; INSERM, Centre de recherche Cardio-Thoracique de Bordeaux, U1045, 33000 Bordeaux, France.

Sébastien Hascoët (S)

Department of Pediatric and adult congenital heart diseases, M3C Marie-Lannelongue Hospital, Paris-Sud University, 92350 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH